Nailing the Right Dose! The Key for Developing Glycine Transporter Inhibitors for Schizophrenia

D ’Souza et al. (1) must be congratulated for their rigorous attempt to characterize the relationship between doses, central occupancy, and relevant pharmacodynamic effects by the glycine transporter-1 (GlyT1) inhibitor PF-03463275. Such studies are essential to inform optimal dose selection for ef ficacy studies and thus provide a critical and indispensable contribution of academia to successful drug development. The conduct and results of their studies highlight methodological and pharmacological issues that are highly relevant for drug development in general and compounds targeting the N-me thyl-D-aspartate receptor (NMDAR) in particular.
Source: Biological Psychiatry - Category: Psychiatry Authors: Tags: Commentary Source Type: research